Coagulation Factor VIIa (recombinant)-jncw [Sevenfact]

Sevenfact is covered for treatment and control of bleeding episodes in patients ≥12 years with hemophilia A or B with inhibitors only for FDA‑approved indications (non‑FDA indications excluded) and is for intravenous use only. Approval requires documentation of the FDA‑approved diagnosis and that applicable coverage/safety criteria are met, with initial authorization for 3 months and renewals for 12 months.

"Sevenfact is a coagulation factor VIIa concentrate indicated for the treatment and control of bleeding episodes occurring in adults and adolescents (12 years of age and older) with hemophilia A or ..."

Sign up to see full coverage criteria, indications, and limitations.